Tuberculosis and Respiratory Diseases

The Korean Academy of Tuberculosis and Respiratory Diseases (대한결핵및호흡기학회)
권호 표지

Correlation Between NT-proBNP and Pulmonary Arterial Pressure in COPD Patients

만성 폐쇄성 폐질환 환자에서 뇌나트륨이뇨펩티드와 폐동맥압과의 상관관계에 관한 연구

  • Hwang, Yong Il (Department of Internal Medicine, Seoul National University, College of Medicine, Lung Institute of Seoul National University Medical Research Center) ;
  • Park, Geun Min (Department of Internal Medicine, Seoul National University, College of Medicine, Lung Institute of Seoul National University Medical Research Center) ;
  • Kwon, Sung Youn (Department of Internal Medicine, Seoul National University, College of Medicine, Lung Institute of Seoul National University Medical Research Center) ;
  • Yoon, Ho Il (Department of Internal Medicine, Seoul National University, College of Medicine, Lung Institute of Seoul National University Medical Research Center) ;
  • Lee, Choon-Taek (Department of Internal Medicine, Seoul National University, College of Medicine, Lung Institute of Seoul National University Medical Research Center) ;
  • Han, Sung Koo (Department of Internal Medicine, Seoul National University, College of Medicine, Lung Institute of Seoul National University Medical Research Center) ;
  • Shim, Young Soo (Department of Internal Medicine, Seoul National University, College of Medicine, Lung Institute of Seoul National University Medical Research Center) ;
  • Lee, Jae Ho (Department of Internal Medicine, Seoul National University, College of Medicine, Lung Institute of Seoul National University Medical Research Center)
  • 황용일 (서울대학교 의과대학 내과학 교실 및 폐연구소) ;
  • 박근민 (서울대학교 의과대학 내과학 교실 및 폐연구소) ;
  • 권성연 (서울대학교 의과대학 내과학 교실 및 폐연구소) ;
  • 윤호일 (서울대학교 의과대학 내과학 교실 및 폐연구소) ;
  • 이춘택 (서울대학교 의과대학 내과학 교실 및 폐연구소) ;
  • 한성구 (서울대학교 의과대학 내과학 교실 및 폐연구소) ;
  • 심영수 (서울대학교 의과대학 내과학 교실 및 폐연구소) ;
  • 이재호 (서울대학교 의과대학 내과학 교실 및 폐연구소)
  • Received : 2007.06.14
  • Accepted : 2007.10.24
  • Published : 2007.10.30
Download PDF
⟨ Previous Next ⟩

Abstract

Background: Pulmonary hypertension is one of the cardiovascular complications of in COPD. However, a diagnosis of pulmonary hypertension requires an invasive test, such as right heart catheterization. NT-proBNP is a cardiac hormone that is elevated when a cardiac volume or pressure overload is present. It was hypothesized that NT-proBNP might play a role in detecting of pulmonary hypertension in COPD patients. Method: The 31 COPD patients, who underwent all of NT-proBNP, echocardiography, and spirometry in Seoul National University Bundang Hospital during the period from November 2003 to July 2005, were retrospectively analyzed. Result: Of the 31 COPD patients, 9 patients had pulmonary hypertension. A significant positive correlation was observed between the NT-proBNP and pulmonary arterial pressure (r=0.589, p=0.002). However, there was no significant correlation observed between the $FEV_1$ and NT-proBNP and $FEV_1$ and pulmonary arterial pressure. Conclusion: NT-proBNP might indicate the presence of pulmonary hypertension in COPD patients.

연구 배경: 폐동맥 고혈압은 만성 폐쇄성 폐질환 환자에서 중요한 심혈관계 합병증이다. 뇌나트륨이뇨펩티드는 허혈성 심질환과 심부전의 경우에서 진단적 효율성과 예후 예측인자로서의 효율성이 잘 알려져 있고 우심에 압력 과부하가 있는 상황에서도 증가된다. 뇌나트륨이뇨펩티드의 측정이 만성 폐쇄성 폐질환 환자에서 폐동맥 고혈압의 진단에 유용성이 있는지 알아보고자 폐동맥압과 뇌나트륨이뇨펩티드와의 상관관계를 분석하였다. 연구 방법: 의무 기록 분석을 통하여 뇌나트륨이뇨펩티드, 심초음파, 폐기능 검사를 모두 실시한 만성 폐쇄성 폐질환 환자들을 대상으로 연구를 수행하였다. 뇌나트륨이뇨펩티드(NT-proBNP), 폐동맥압(PAP), 1초간 노력성 폐활량($FEV_1$)과의 상관관계를 분석하였다. 결과: 총 31명의 환자가 분석에 포함되었으며 폐동맥 고혈압이 동반된 환자는 9명(26.7%)이었다. 폐동맥압과 뇌나트륨이뇨펩티드 사이에 유의한 상관관계가 관찰되었다(r=0.589, p=0.002). 결론: 뇌나트륨이뇨펩티드는 만성 폐쇄성 폐질환 환자들에서 동반된 폐동맥 고혈압의 진단에 사용될 수 있을 것으로 사료된다.

Keywords

References

  1. National Heart, Lung, and Blood Institute and World Health Organization. Global initiative for chronic obstructive lung disease: global strategy for the diagnosis) management, and prevention of chronic obstructive pulmonary disease. National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA [revised 2006]. Available from: URL: http://www.goldcopd.com
  2. Kim DB, Kim YS, Jung K-S, Chang JH, Lim CM, Lee JH, et a1. Prevalence of chronic obstructive pulmonary disease in Korea. Am J Respir Crit Care Med 2005;172:842-7 https://doi.org/10.1164/rccm.200502-259OC
  3. Agusti AG, Noguem A, Sauleda J, Sala E, Pons J, Busquets X. Systemic effects of chronic obstructive pulmonary disease. Eur Respir J 2003;21:347-60 https://doi.org/10.1183/09031936.03.00405703
  4. Higenbottarn T. Pulmonary hypertension and chronic obstructive pulmonary disease: a case for treatment. Proc Am Thorac Soc 2005;2:12-9
  5. Naeije R. Pulmonary hypertension and right heart failure in chronic obstructive pulmonary disease. Proc Am Thome Soc 2005;2:20-2
  6. Barbera JA, Peinado VI, Santos S. Pulmonary hypertension in chronic obstructive pulmonary disease. Eur Respir J 2003;21:892-905 https://doi.org/10.1183/09031936.03.00115402
  7. Naeije R, Barbera JA. Pulmonary hypertension associated with COPD. Crit Care 2001;5:286-9 https://doi.org/10.1186/cc1049
  8. Weitzenblun E, Chaouat A. Severe pulmonary hypertension in com is it a distinct disease? Chest 2006;127:1480-2 https://doi.org/10.1378/chest.127.5.1480
  9. Lee-Chiong Jr TL , NMthay RA. Pulmonary hypertension and cor pulmonale in COPD. Semin Respir Crit Care Med 2003;24:263-72 https://doi.org/10.1055/s-2003-41087
  10. Arcasoy SM, Christie JD, Ferrari VA, Sutton MS, Zisman DA, Blumenthal NP, et al. Echocardiographic assessment of pulmonary hypertension in patients with advanced lung disease. Am J Respir Crit Care Med 2003;167:735-40 https://doi.org/10.1164/rccm.200210-1130OC
  11. Kessler R, Faller M, Weilzenhlum E, Chaouat A, Aykut A, Ducolone A, et al. 'Natural history' of pulmonaty hypertension in a series of 131 patients with chronic obstructive lung disease. Am J Respir Crit Care Med 2001;164:219-24 https://doi.org/10.1164/ajrccm.164.2.2006129
  12. Bossone E, Bodini BD, Mazza A, Allegra L Pulmonary arterial hypertension: the key role of echocardiography. Chest 2005;127:1836-43 https://doi.org/10.1378/chest.127.5.1836
  13. Kim NH. Diagnosis and evaluation of patient with pulmonaty hypertension. Cardiol Clin 2004;22:367-73 https://doi.org/10.1016/j.ccl.2004.04.003
  14. Yap LB, rvlukerjee D, Timms PM, Ashrafjan H, Coghlan JG.. Natriuretic peptides, respiratory disease, and right heart. Chest 2004;126:1330-6 https://doi.org/10.1378/chest.126.4.1330
  15. Ruskoaho H Caridac hormones as diagnostic tools in heart failure. Endocr Rev 2003;24:341-66 https://doi.org/10.1210/er.2003-0006
  16. Clerico A, Emdin M Diagnostic accuracy and plugnostie relavance of measurement of cardiac natriuretic peptkdes: a review. Clin Chem 2004;50:33-50 https://doi.org/10.1373/clinchem.2003.024760
  17. McQuillan BM, Picard MH, Leavitt M, Weyman AE. Clinical oorlelates and reference intervals for pulmonary arterial systolic pressure among echocar-diographically normal subjects. Circulation 2001;104:2797-802 https://doi.org/10.1161/hc4801.100076
  18. Barst RJ, McGoon M, Torbicki A, Sitbon O, Krowka MJ, Olschewski H, et al. Diagnosis and differential assessment of pulmonaty arterial hypertension. J Am Coli Cardiol 2004;43:408-78
  19. Voelkel NF, Cool CD. Pulmonary vascular involvement in chronic obstructive pulmonary disease. Eur Respir J Suppl 2003;46:28S-32S
  20. Chaouat A, Bugnet A, Kadaoui N, Schott R, Enache I, Thlcolone A, et al. Severe pulmonary hypertension and clu'Onic obstructive pulmonary disease. Am J Respir Crit Care Med 2006;172:189-94 https://doi.org/10.1164/rccm.200401-006OC
  21. Scharf SM, Iqbal M, Keller C, Criner G, Lee S, Fessler HE; National Emphysema Treatment Trial (NETT) Research Group. Hemodynamic characterization of patients with severe emphysema. Am J Respir Crit Care Med 2002;100:314-22
  22. Mitchell RS, Vincent Th, Ryan S, Pilley GP. Chrunic obstructive bronchopubnonary disease, IV: 'The clinical and physiological difference of chronic bronchitis and emphysema. Am J Med Sci 1964;247:513-7 https://doi.org/10.1097/00000441-196405000-00001
  23. Renzetti AD Jr, McClement JH, Litt ED. The Veterans Administration cooperative study of pulmonary function, 3. Mortality in relation to respiratory function in chronic obstructive pulmonary disease. Am J Med 1966;41:115-29 https://doi.org/10.1016/0002-9343(66)90009-X
  24. Nagaya N, Nishikimi T, Uematsu M, Satoh T, Kyotani S, Sakamaki P, et al. Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. Circulation 2000;102:865-70 https://doi.org/10.1161/01.CIR.102.8.865
  25. Bando M, Ishii Y, Sugiyama Y, Kitamura S. Elevated plasma brain natriuretic peptide levels in chronic respiratory failure with cor pulmonale. Respir Med 1999;93:507-14 https://doi.org/10.1016/S0954-6111(99)90094-X
  26. Ishii J, Nomura M, lto M, Naruse H, Mori Y, Wang JH, et al. Plasma concentration of brain natriuretic peptide as a biochemical marker for evaluation of right ventricular overload and mortality in chronic respiratory disease. Clin Chim Acta 2000;301:19-30 https://doi.org/10.1016/S0009-8981(00)00312-0
  27. Nagaya N, Nishilcimi T, Okano Y, Uematsu M, Satoh T, Kyotani S, et al. PIasma brain natiruretic peptide levels increase in proportion to extent of light ventricular dysfunction in pulmonary hypertension. J Am Coli Cardiol 1998;31:202-8 https://doi.org/10.1016/S0735-1097(98)81518-0
  28. Ueda R, Yokouchi M, Suzuki T, aromo E, Katagiri T. Prognostic value of high plasma brain natriuretic peptide concentrations in very elderly persons. Am J Med 2003;114:266-70 https://doi.org/10.1016/S0002-9343(02)01525-5